Nektar Therapeutics

Last updated
Nektar Therapeutics
FormerlyInhale Therapeutic Systems, Inc.
Company type Public
Industry Biopharmaceuticals
Founded1990;34 years ago (1990)
Headquarters San Francisco, California, U.S.
Products
Revenue US$1.13 billion (2018) [1]
Number of employees
718 (2020)
Website nektar.com

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. [2] The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances. [3] It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. [2] The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. [4]

Contents

Background

The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. [2] The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc. [5]

In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. [6] The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. [7] As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion. [1] As of July 15, 2019, the company had a market cap of $5.88 Billion.

Pipeline

Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. [8] The European Medicines Agency refused a marketing authorisation in 2017. [9]

Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, [10] Phase I results were announced in November 2016. [11] It is now in a phase 2 trial in combination with nivolumab for various advanced cancers. [12]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

Medarex was an American biopharmaceutical company based in Princeton, New Jersey, with manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. In 2009, Medarex was purchased by Bristol Myers Squibb.

<span class="mw-page-title-main">Acorda Therapeutics</span> American biotechnology company

Acorda Therapeutics, Inc. is an American biotechnology company based in Pearl River, New York. The company develops therapies that improve neurological function in people with Parkinson's disease, multiple sclerosis and other neurological disorders. Acorda Therapeutics manufactures and markets the drugs Inbrija and Ampyra (dalfampridine) in the United States.

<span class="mw-page-title-main">Nivolumab</span> Anticancer medication

Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction cancer. It is administered intravenously.

<span class="mw-page-title-main">Naloxegol</span> Medication used in the treatment for Opioid-Induced Constipation

Naloxegol is a peripherally acting μ-opioid receptor antagonist developed by AstraZeneca, licensed from Nektar Therapeutics, for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe and well tolerated for 52 weeks. When given concomitantly with opioid analgesics, naloxegol reduced constipation-related side effects, while maintaining comparable levels of analgesia.

Trius Therapeutics was a biopharma company based in San Diego, CA that focused on the development of antibiotics.

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.

<span class="mw-page-title-main">Neogen</span> International food safety company

Neogen Corporation is an international food safety company that provides test kits and relevant products to detect dangerous substances in food. The company was founded in 1982 and is based in Lansing, Michigan. The company serves a wide range of countries including Canada, United States, the United Kingdom, parts of Europe, Mexico and Brazil, India, and China, among others. As of 2016, the company has a market capitalization of $1.83 billion with an enterprise value of $1.57 billion. The company operates a product line of over 100 drug detection test kits worldwide for the detection of about 300 abused and therapeutic drugs in animal treatment. In 2009, it became a vendor of the Chinese government and has been engaged in researching China-specific food safety and plant health issues.

Varlilumab is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies. It is an anti-CD27 antibody and helps activate T-cells.

<span class="mw-page-title-main">Immune checkpoint</span> Regulators of the immune system

Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. However, some cancers can protect themselves from attack by stimulating immune checkpoint targets.

<span class="mw-page-title-main">Sotio</span>

SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.

Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for Chapter 11 bankruptcy.

<span class="mw-page-title-main">Etirinotecan pegol</span> Pharmaceutical drug

Etirinotecan pegol is a drug developed by Nektar Therapeutics for the treatment of certain kinds of breast cancer with brain metastases. The European Medicines Agency refused to grant it a marketing authorisation in 2017.

Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.

Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.

References

  1. 1 2 "NKTR Key Statistics | Nektar Therapeutics Inc Stock - Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-16.
  2. 1 2 3 "BDR: Summary for Nektar Therapeutics, Inc.- Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-17.
  3. ↑ "Nextar Therapeutics Inc. brief introduction NASDAQ". Nasdaq.com. Retrieved 2014-03-16.
  4. ↑ Totty, Michael (2006-09-11). "The Winners Are..." Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-01-22.
  5. ↑ "NKTR reuter.com". Reuters.com. Archived from the original on 2014-03-16. Retrieved 2014-03-16.
  6. ↑ "Nektar Therapeutics : U.S. Patents Awarded to Inventors in Alabama (Feb. 8)". 4-traders.com. 2014-02-08. Retrieved 2014-03-16.
  7. ↑ "Nextar Marketwatch Quote Summary". Marketwatch.com. Retrieved 2014-03-16.
  8. ↑ Kuznar, Wayne (28 June 2016). "Novel Agents are Targeting Drivers of TNBC: Several drug candidates in I-SPY2 have 'graduated' to later-phase studies". Medpage Today. Retrieved 23 February 2024.
  9. ↑ "Onzeald". European Medicines Agency. 2017-11-10.
  10. ↑ "Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine". Nektar Therapeutics. June 2, 2015. Archived from the original on 19 December 2017. Retrieved 25 June 2015.
  11. ↑ Martins, Ines (17 November 2016). "Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Study" . Retrieved 2020-11-12.
  12. ↑ Inman, Silas (12 November 2017). "NKTR-214/Nivolumab Combination Shows Promise in Early Study". OncLive. Retrieved 12 November 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.